Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations

Oncogenic mutations in KRAS can be recognized by T cells on specific class I human leukocyte antigen (HLA-I) molecules, leading to tumor control. To date, the discovery of T cell targets from KRAS mutations has relied on occasional T cell responses in patient samples or the use of transgenic mice. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jaewon, Goulding, Scott P., Conn, Brandon P., McGann, Christopher D., Dietze, Jared L., Kohler, Jessica, Lenkala, Divya, Boudot, Antoine, Rothenberg, Daniel A., Turcott, Paul J., Srouji, John R., Foley, Kendra C., Rooney, Michael S., van Buuren, Marit M., Gaynor, Richard B., Abelin, Jennifer G., Addona, Terri A., Juneja, Vikram R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017224/
https://www.ncbi.nlm.nih.gov/pubmed/35474673
http://dx.doi.org/10.1016/j.crmeth.2021.100084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017224/
https://www.ncbi.nlm.nih.gov/pubmed/35474673
http://dx.doi.org/10.1016/j.crmeth.2021.100084

Ejemplares similares